For its second fiscal quarter (ending June 30), Ascendis Pharma AS (NASDAQ: ASND) has reported E.P.S. of $-2.03 compared to $-2.37 a year ago. This performance was $-0.48 short of the consensus estimate of $-1.55. E.P.S. were $-9.44 for the latest four quarters through June 30 versus $-11.80 for the same period a year ago.
Recent Price Action
On 9/3/24, Ascendis Pharma AS (NASDAQ: ASND) stock declined by -2.7%, closing at $134.68. Moreover, trading volume in this decline was unusually high at 186% of normal. The stock has performed in line with the market over the last nine months and has declined -3.6% during the last week.
Current PriceTarget Research Rating
ASND is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Ascendis Pharma AS is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment